Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])[C@@H](O)C=C4C[C@@H](O)CC[C@]34C
InChI
InChIKey=OEVZKEVBDIDVOI-YSZCXEEOSA-N
InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:29:15 GMT 2023
by
admin
on
Fri Dec 15 16:29:15 GMT 2023
|
| Record UNII |
Q0CZ537GC8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2697-85-0
Created by
admin on Fri Dec 15 16:29:15 GMT 2023 , Edited by admin on Fri Dec 15 16:29:15 GMT 2023
|
PRIMARY | |||
|
DTXSID201043225
Created by
admin on Fri Dec 15 16:29:15 GMT 2023 , Edited by admin on Fri Dec 15 16:29:15 GMT 2023
|
PRIMARY | |||
|
Q0CZ537GC8
Created by
admin on Fri Dec 15 16:29:15 GMT 2023 , Edited by admin on Fri Dec 15 16:29:15 GMT 2023
|
PRIMARY | |||
|
DB06257
Created by
admin on Fri Dec 15 16:29:15 GMT 2023 , Edited by admin on Fri Dec 15 16:29:15 GMT 2023
|
PRIMARY | |||
|
9818024
Created by
admin on Fri Dec 15 16:29:15 GMT 2023 , Edited by admin on Fri Dec 15 16:29:15 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Status: 606 - Abandoned - No Statement Of Use Filed
|
||
|
ACTIVE MOIETY |
HE-2200 has been in phase II clinical trials for the treatment of inflammatory bowel diseases and multiple sclerosis. However, this research has been discontinued. The compound was originally developed by Virginia Commonwealth University (VCU), and licensed to Harbor BioSciences (formerly Hollis-Eden Pharmaceuticals).
|
